Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). [electronic resource]
Producer: 20051013Description: 485-93 p. digitalISSN:- 1523-6838
- Albuminuria -- epidemiology
- Angiotensin II Type 1 Receptor Blockers -- therapeutic use
- Angiotensin-Converting Enzyme Inhibitors -- therapeutic use
- Antihypertensive Agents -- therapeutic use
- Blood Pressure
- Body Mass Index
- Creatinine -- blood
- Diabetes Mellitus, Type 2 -- complications
- Diabetic Nephropathies -- epidemiology
- Disease Progression
- Double-Blind Method
- Female
- Fenofibrate -- administration & dosage
- Fibrinogen -- analysis
- Follow-Up Studies
- Glycated Hemoglobin -- analysis
- Homocysteine -- blood
- Humans
- Hyperlipidemias -- complications
- Hypertension -- complications
- Hypolipidemic Agents -- administration & dosage
- Incidence
- Male
- Middle Aged
- Models, Biological
- Smoking -- epidemiology
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.